Brokerages Set Phibro Animal Health Corporation (NASDAQ:PAHC) PT at $38.80

Phibro Animal Health Corporation (NASDAQ:PAHC) has received a consensus rating of “Hold” from the seven research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $38.80.

Several equities research analysts have recently issued reports on PAHC shares. Weiss Ratings downgraded shares of Phibro Animal Health from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Morgan Stanley set a $49.00 price objective on shares of Phibro Animal Health in a research note on Friday, February 6th. Citigroup lowered their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating on the stock in a research note on Thursday, May 14th. Finally, Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 21st.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 4,528 shares of Phibro Animal Health stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total transaction of $219,562.72. Following the sale, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. The trade was a 7.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 74,928 shares of company stock worth $4,017,273 in the last 90 days. 50.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Phibro Animal Health by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 1,539,593 shares of the company’s stock worth $57,519,000 after buying an additional 13,884 shares in the last quarter. State Street Corp boosted its stake in Phibro Animal Health by 5.4% during the fourth quarter. State Street Corp now owns 942,279 shares of the company’s stock worth $35,204,000 after buying an additional 48,243 shares in the last quarter. Millennium Management LLC boosted its stake in Phibro Animal Health by 4,227.1% during the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company’s stock worth $23,959,000 after buying an additional 626,492 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Phibro Animal Health by 5.8% during the first quarter. Renaissance Technologies LLC now owns 576,735 shares of the company’s stock worth $31,899,000 after buying an additional 31,435 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Phibro Animal Health by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 569,111 shares of the company’s stock worth $21,265,000 after buying an additional 21,951 shares in the last quarter. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Trading Down 1.8%

Shares of Phibro Animal Health stock opened at $32.43 on Monday. The company’s fifty day simple moving average is $46.18 and its 200-day simple moving average is $45.14. The company has a market cap of $1.32 billion, a price-to-earnings ratio of 13.92, a PEG ratio of 0.50 and a beta of 0.46. The company has a current ratio of 3.17, a quick ratio of 1.26 and a debt-to-equity ratio of 1.97. Phibro Animal Health has a 1 year low of $22.85 and a 1 year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million for the quarter, compared to the consensus estimate of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, sell-side analysts expect that Phibro Animal Health will post 3.07 EPS for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Shareholders of record on Wednesday, June 3rd will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 1.5%. Phibro Animal Health’s payout ratio is currently 20.60%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.